Background: Post-infectious irritable bowel syndrome (PI-IBS) prevalence, small intestinal bacterial overgrowth (SIBO), altered microbiota, low-grade inflammation, and antibiotic therapy in IBS are all controversial issues.
Introduction
The pathophysiology of irritable bowel syndrome (IBS) is not completely understood, but various mechanisms such as gastrointestinal motility disturbances, visceral hypersensitivity, altered bidirectional brain-gut communication, psychosocial alterations, and stress have been proposed. 1 More recently a group of patients has been described that develop IBS after gastrointestinal infections, known as post-infectious (PI) IBS. 2 Likewise, the presence of small intestinal bacterial overgrowth (SIBO) in quantitative and qualitative gut and fecal microbiota disruptions has been reported. 3 ---4 IBS has also been associated with the presence of low-grade inflammation in the intestinal mucosa resulting from an increase in the number of intraepithelial lymphocytes, mast cells, and enterochromaffin cells, 5 without minimizing the fact that immunity alterations have been described at the peripheral level; such is the case with low levels of interleukin (IL)-10 and the increase of some pro-inflammatory interleukins such as tumor necrosis factor alpha (TNF-␣) and other inflammation mediators. 6 In fact, it is thought that alterations in the microbiota or SIBO in the small bowel could increase intestinal permeability, activating submucosal immunologic mechanisms that in turn could lead to low-grade inflammation. 7 Furthermore, the mediators of this immunologic activation could stimulate enteric nervous system terminals, and even the autonomic nervous system, triggering the visceral sensitivity and motility alterations that have been described in IBS. 7 ---8 On the other hand, the presence of PI-IBS, changes in the microbiota, and the association with SIBO in IBS have brought about the justification of antibiotic use in IBS treatment. 8 ---9 Nevertheless, despite all the above, evidence is sometimes controversial. On the one hand, only one group of patients develops PI-IBS and not all the patients present with SIBO. 9---10 The latter is even more limited due to the fact that the breath tests for diagnosing SIBO have not been standardized and vary among studies. 11 Moreover, the disturbances in the microbiota are diverse and there is a wide variety of techniques for studying them, including the most sophisticated genomic tests. 12 Similarly, the presence of low-grade inflammation is not universal and the alterations described differ among studies, in fact, it is uncertain whether these changes that present in some IBS patients are related only to PI-IBS. 13 Finally, the studies on antibiotics in IBS have evaluated different doses, for different periods of time, and different outcome variables. 14---15 Consequently, our aim was to carry out an evidencebased review on the following aspects of IBS: 1. The frequency of SIBO in IBS. 2. The incidence and prevalence of PI-IBS and its risk factors. 3. To determine the alterations in the intestinal and/or fecal microbiota in IBS. 4 . To determine the presence of bowel inflammation in IBS, analyzing the differences between PI-IBS and non PI-IBS. 5. To understand the altered intestinal function (motility, secretion, visceral sensitivity) in IBS, in relation to PI-IBS, SIBO, and microbiota disturbances. 6. To evaluate antimicrobial treatment in IBS.
Methods

Coordinator and reviewers
This initiative was carried out by a group of Mexican gastroenterologists interested in the subject. The coordinator of the group is an IBS expert (MS) and the participants were chosen based on their experience in gastroenterology and their training and participation in clinical and basic research related to the theme. An expert in the classification of levels of evidence and grades of recommendation (MP) with experience and training in gastroenterology, as well as clinical and statistical research, but who is not an IBS expert, was also included in the group. This was purposely done so that there would be both a different perspective and a more objective evidence evaluation. The 9 reviewers were divided into 6 reviewer groups (MB, RC-AH, ALC-JLT, YLV-MAV, MRT and MS), each receiving one of the 6 issues to be reviewed.
The project coordinator did a preliminary literature review in PubMed, using the MEDLINE database and including articles written up to July 2012. The following search terms were employed: «IBS» AND «SIBO», «abnormal breath test», «incidence of post infectious IBS», «prevalence of post infectious IBS», «microbiota», «Post infectious IBS» AND «risk factors», «epidemiology», «low grade inflammation», «Microbiota», «dysbacteriosis», «SIBO», «methane» AND intestinal function», «intestinal motility», «sensory function», «sensory abnormalities», «visceral hypersensitivity».
Once identified, the articles were distributed to those responsible for each theme to be reviewed. Systematic reviews with or without meta-analyses and original articles were selected. Narrative reviews were not included. In addition, the reviewers were authorized to include articles that were not selected in the initial review, but that were identified from other sources, such as from the references of an article originally chosen, or articles published after July 2012 and up to August 31, 2013 , when the preparation of the manuscript concluded. All participants received a set of instructions by email with respect to the information to be obtained from the publications, as well as the methodology for classifying the levels of evidence and grades of recommendation.
Evidence grading
The reviewers analyzed the evidence and elaborated statements based on the available information. The levels of evidence and grades of recommendation were evaluated and graded using the Oxford Centre for Evidence-Based Medicine (OCEBM) system. 16 This system utilizes numbers and letters to evaluate the quality and the level of evidence of clinical studies. Quality and methodology are established with the numbers 1 through 5 and the lower case letter «a», «b», or «c». The numbers indicate the quality of the studies and the letters indicate the methodology employed. For example, a 1a study is usually a systematic review that only includes high quality, homogeneous, controlled clinical trials (the number 1 indicates that only high quality homogeneous controlled clinical trials were included and the letter «a» indicates that it is a systematic review); a 2 a study is a systematic review (letter «a») that includes cohort studies of different quality that are methodologically considered to be of lower quality and level (number 2) than the controlled clinical trials. A final example: 2 b is a single individual cohort or a single controlled clinical trial (letter «b») of low quality (number 2).
The grade of recommendation is given in the upper case letters A through D. The letter A is for statements, conclusions, or recommendations based on information obtained from high quality or level 1 evidence, whereas letter D is given to recommendations based on studies of low scientific quality or level 5 evidence.
Evidence analysis
The first face-to-face meeting of the group was held in August 2012 and lasted 9 hours. First the OCEBM system was discussed and then the reviewers presented a summary of each selected article in tables, including authors, journal, year, country, type of article (systematic review or original) and design, diagnostic criteria for IBS, and other selection criteria for the subjects, study methods and/or evaluated treatment, outcome variables, and results or conclusions. In addition, the reviewers responsible for each theme proposed a level of evidence for each of the studies and then presented the statements or declarations and their grades of recommendation. Each of the assigned levels of evidence was discussed and were modified and accepted by consensus; the same was done for the grades of recommendation. Finally, the coordinator presented a summary of each one and its pending work. In January 2013 the second meeting was held, lasting 8 hours, and only the 6 updated reviews were presented. Then in March 2013 each reviewer sent his or her written participation to the coordinator who then sent each of the sections to be cross-reviewed. In other words, each reviewer or reviewer group went over another group's section. Once this cross-review was completed, the coordinator proceeded to edit the manuscript, after which it was reviewed again by all the participants.
Results
In the preliminary PubMed review, 183 references were identified; 60 were eliminated because they were duplicated, leaving 123 selected articles. Later, 9 additional articles from other sources were added. The articles identified in the initial search and those selected from other sources are described in each section. The results of the 6 aspects covered in the review are described below. Each section begins with the statements and their respective levels of evidence and grades of recommendation, followed by the corresponding summary. Twenty-four articles were identified that reported on the prevalence of SIBO in IBS; 3,11,17---38 23 articles during the initial search, 3,11,17---35,37---38 and an additional article identified through manual search during the preparation of the document. 36 Tw o systematic reviews with a meta-analysis that included more than 3,400 subjects and compared patients with IBS and healthy controls showed that the breath tests for SIBO were abnormal in the patients, with a 4-times higher probability than the controls. 3, 17 An extensive bibliographic search was carried out in both reviews, the studies were adequately selected, and the authors made a clear reference to the heterogeneity of the studies (Table 1) .
On the other hand, a case series of patients with IBS that participated in an open study with rifaximin, showed a SIBO prevalence of 71% with LBT in IBS. 37 In addition, 16 case-control studies 11,18---30,36,38 provided information on SIBO prevalence in IBS, including the study by Pimentel et al.; 18 the prevalence of this comparative controlled clinical trial with placebo was the result of a sub-analysis of the study population. A second study analyzed a series of consecutive patients with diverse digestive disorders that were referred for upper endoscopy; they had duodenal aspiration culture done to determine SIBO and IBS was considered a posteriori. 36 In this same study SIBO was also compared in those patients with IBS-D and IBS-Non D, which made it incomparable with all the other studies. 36 Of the 14 remaining studies, 5 demonstrated greater SIBO prevalence in IBS compared with the controls; 3, 17, 19, 24, 38 7 showed equal prevalence, 11,20---22,26---27,30 one showed lower prevalence in IBS, 28 and one did not report the p value, although there appeared to have been a greater prevalence in IBS 23 ( Table 1) . Among the analyses with greater prevalence in IBS, the study by Pimentel et al. stands out because it analyzed the prevalence of SIBO among patients with fibromyalgia, IBS, and healthy controls. 19 The patients with fibromyalgia were selected regardless of their digestive symptoms and were the group with the highest SIBO prevalence, above that of the IBS patients and the healthy controls (100, 84, and 20%, respectively). It should be stressed that only one Latin American study was identified. 21 In this study, Madrid et al., in Chile, found that the prevalence of SIBO was similar in patients with IBS, compared with that of other functional gastrointestinal disorders (IBS: 76%; functional constipation: 73%; functional diarrhea: 69%; and functional bloating: 68%). 21 Another study analyzed patients treated with proton pump inhibitors (PPIs) vs those that were not, finding no apparent differences in SIBO frequency. 25 And finally, two other studies compared IBS vs other functional gastrointestinal disorders (FGIDs). 26, 29 Six case series with a combined total of 478 patients were analyzed as well, and a prevalence of SIBO was reported in patients with IBS that varied from 36 to 74%, depending on the methods employed. 31---35,37 The use of breath tests for diagnosing SIBO has been characterized by the lack of a standardized methodology and validated criteria for defining an abnormal test. In the majority of the studies lactulose was the substrate, but with a wide variety of doses, protocols for carrying out the tests, and criteria for determining that a test is abnormal. Walters et al. used the LBT and applied 2 different criteria in their interpretation. 20 They included 39 patients with IBS and 20 healthy controls, finding a radically different SIBO prevalence in patients with IBS, even though there was no difference in the comparison with the healthy controls, regardless of the criterion used: 28% of the patients with IBS vs 30% of the control subjects when the criterion of more than 20 ppm of H 2 in the first 90 min of the test was used, compared with 69% of the patients with IBS vs 75% of the controls when the criterion of more than 20 ppm of H 2 at any time during the first 180 min of the test was employed. 20 Furthermore, the accuracy of the LBT has been questioned because the decomposition of this substrate by the bacteria of the cecum usually produces a second spike in hydrogen detection that reduces its specificity. In contrast, the GBT, in which the substrate is completely absorbed in the proximal small bowel (duodenum), has shown a greater sensitivity and specificity for the detection of SIBO than the LBT. 11 Rana et al. found a similar SIBO prevalence in IBS patients and healthy subjects utilizing the LBT (34 vs 30%, p = NS), but a higher prevalence of SIBO in IBS utilizing the GBT (6.2 vs 0.66%, p < 0.01). 30 Despite its apparently being a more precise test, it has been employed in fewer studies. 24, 27, 32, 36 Sucrose, another substrate that is totally absorbed in the small bowel and therefore theoretically more accurate, was used in only one of the selected studies. 23 On the other hand, the presence of SIBO has also been defined based on the detection of an elevated bacterial count from small bowel fluid culture. The quantitative culture should then be regarded as the benchmark test for SIBO, but it has been utilized in very few studies. However, it would depend on the culture site and many bacteria are unculturable. Only 2 of the selected studies employed culture for detecting SIBO, 22, 28 and as mentioned before, one of them reported a lower SIBO frequency in IBS vs control subjects with different pathologies that underwent endoscopy. 28 We can therefore conclude that there is evidence suggesting a greater probability of SIBO in IBS according to breath test data, but there is not enough evidence for recommending the routine use of these tests for diagnosing SIBO in IBS. Twenty-six published articles were identified that studied the composition of the microbiota in patients with IBS; 24 in the initial search 41---64 and 2 from other sources. 39, 40 All of them are case-control studies conducted in Europe, Asia, and the United States; none from Latin America or Africa. Twenty-five were carried out on adult population 39---55,57---64 and only one on children. 56 In 11 of the studies, the cases were classified according to the IBS subtype. 41,43,46---48,52,55---56,60,62,64 The microbiota was analyzed with molecular methods in the majority of the studies, whereas just fecal culture was used in 2, 39, 40 and both methodologies were used in 4 studies. 42, 48, 51, 58 Even though the majority of the studies analyzed the composition of the microbiota in samples of fecal matter, the microbial composition was also examined in biopsies of the colonic mucosa in 4 of the studies. The predominant results of each of these studies and the summary of the microbial ecology of the gut microbiota in IBS are shown in Table 2 .
2. Alterations in the gut
The investigations that used fecal cultures for studying the gut microbiota have shown that IBS patients, unlike healthy subjects, have a diminished population of bifidobacteria and lactobacilli and an increased population of streptococci, coliforms, and Clostridium species. 39, 40, 42, 51 Moreover, the majority of the studies used molecular methods independent of the culture, such as tests based on DNA extraction and amplification of the 16S genes of ribosomal RNA, quantitative PCR, the products of PCR through denaturing gradient gel electrophoresis, and probe-specific fluorescence in situ hybridization. The many different molecular strategies employed in these studies (Table 3) is the reason for the inconsistent and even contradictory results in relation to the composition and diversity of the microbiota in patients with IBS, as well as a single determination of the microbiota in the variable of time and the limited knowledge of new bacterial species that are still waiting to be described. Thus, even though it seems that the gut microbiota of patients with IBS is different from that of the controls, it is not yet possible to establish an intestinal microbial composition characteristic of IBS.
3. Incidence and prevalence of post-infectious irritable bowel syndrome (PI-IBS)
• The average incidence of PI-IBS has been reported as 9 to 10% with a 4 to 36% interval (level 1 a evidence, grade A recommendation).
• The prevalence of PI-IBS varies from 3 to 17% and decreases over time after gastrointestinal infection (level 3 b evidence, grade B recommendation). • The most studied etiology in relation to PI-IBS is that of bacterial origin, and even though the viral and parasitic causes have scarcely been studied, they also appear to be risk factors for PI-IBS (level 2 b evidence, grade B recommendation).
Twenty-three studies on PI-IBS were reviewed, 19 of which were identified in the initial search 10,65---82 and 4 afterwards from other sources. 83---86 Twelve studies reported the incidence of PI-IBS (new onset IBS), 65---67,71---72,75,77,80,83,85 8 reported the prevalence, 65, 69, 73, 74, 78, 79, 82, 84 and 8 analyzed the risk factors related to the development of PI-IBS. 10, 66, 70, 72, 82, 84, 86 All the studies were conducted on adult population, with the exception of one on pediatric population 71 ( Table 4 ). The incidence of clinical symptoms of IBS after a gastrointestinal infection has been reported at an average of 9-10% based on 2 systematic reviews, but varies depending on the case from 4 to 36%. 65, 67 There are no differences if IBS develops after an acute gastroenteritis episode during epidemics, due to isolated infections, or after traveler's diarrhea. 65 Likewise, the probability of developing IBS is 6 times higher in subjects that have been exposed to gastrointestinal infections than in those that have not. 66 The prevalence of PI-IBS has been reported in 7 to 33% of patients, but there are wide variations depend- The studies are organized from higher to lower level of evidence and then in the progressive order of publication year. A: alternating; C: constipation; D: diarrhea; DNA: deoxyribonucleic acid; FISH: fluorescence in situ hybridization; H2: hydrogen; IBS: irritable bowel syndrome; IQR: interquartile range; LE: level of evidence; N: number; PCR-DGGE: polymerase chain reaction-denaturing gradient gel electrophoresis; qPCR: quantitative polymerase chain reaction; RCT: randomized controlled trial; rRNA: ribosomal ribonucleic acid; spp: all the species of the genus referred to; UC: nonspecific chronic ulcerative colitis; >: increase; <:decrease;. FISH is a technique that detects the sequences of nucleic acids in bacteria and tissue. In situ detection provides direct visualization of the special location of specific sequences, which is crucial for explaining the genetic organization and function. For this reason the in situ hybridization method is an important technique in the diagnosis of chromosomal rearrangement in microorganism detection. In situ hybridization is based on the complementariness of the nucleic acids of DNA and/or RNA through the hydrogen bridges formed between the bases: adenine-thymine (DNA) or uracil (RNA) and cytosine-guanine (DNA and RNA) PCR-DGGE (amplification by polymerase chain reaction-denaturing gradient gel electrophoresis)
The genetic blueprint technique is useful for identifying bacteria (isolated or in community) at the end of a polymerase chain amplification of its DNA. The genetic print consists of a profile based on the physical separation of the unique sequence of the 16S ribosomal RNA gene through DGGE. It also enables the simultaneous analysis of numerous bacteria from a clinical sample or tissue. Thus the technique makes it possible to compare the genetic diversity of bacteria and the study of their behavior at the same time 16S rDNA (deoxyribonucleic acid)
16S rDNA is the gene that encodes for 16s ribosomal RNA. It is a component of the small subunit of prokaryotic ribosomes. The 16S rDNA gene is used for phylogenetic studies because it is highly conserved among the different bacterial and archaeal species; in addition it contains hypervariable regions that provide specific species sequences that are useful for bacterial identification. The use of these sequences has made it possible to become aware of the existence of a large number of genera and species 16S rRNA (ribonucleic acid) 16S rRNA is a polyribonucleotide of approximately 1.500 nt, encoded by the RRS gene. It is also designated 16s ribosomal DNA (16S rDNA) and phylogenic and taxonomic information can be obtained from its sequencing. Regarded as a molecular chronometer due to the fact that it is an ancient molecule present in all bacteria, 16S ribosomal RNA (rRNA) is the most widely used macromolecule in studies of bacterial phylogeny and taxonomy. The changes in its sequence data occur slowly and its variability enables it to distinguish organisms both nearby and distant Quantitative PCR (deoxyribonucleic acid)
Quantitative polymerase chain reaction (qPCR) or real-time PCR is a variation of the standard PCR technique that is employed to determine the number of DNA or mRNA copies present in a sample (measurement of gene expression). The microorganisms in a sample can be identified and quantified by this technique, which is very useful for the diagnosis and treatment of patients Phylogenetic microarray
Microarrays are made up of biologic or synthetic material and a solid support in which it is immobilized or the biologic material is adsorbed. Microarrays have different applications, such as the detection of genes in a sample (DNA microarrays), the presence of polymorphisms, or the determination of different gene expressions (mRNA microarrays). Microarrays have the advantage that the presence and/or expression of a large number of genes can be analyzed simultaneously. Dendograms, which enable the genetic relation of different samples to be observed, can be constructed through bioinformatic analysis Pyrosequencing Pyrosequencing is a non-fluorescent massive sequencing technique that enables the determination of nucleotide sequences in a sample. One of the advantages of this technique is that if a sample contains a mixture of bacterial species, they can each be identified through the bioinformatic analysis ing on the reported series and particularly on the time of observation. 65 Prevalence also varies depending on the geographic region and Mexico appears to have one of the lowest prevalence rates in the world, at only 5.0%. 79 Prevalence is also higher if it is evaluated sooner rather than later after an infectious outbreak. For example, 2 years after an outbreak of bacterial gastroenteritis in Walkerton (Canada), PI-IBS prevalence was reported in 30.4% of the subjects exposed to acute gastroenteritis. 87 Contrastingly, in the following years the prevalence had decreased and at 8 years it was 15.4%. 70, 88 Similarly, in Sweden the initial PI-IBS prevalence of 12% was reduced to 9%, 5 years later. 84 In large reviews it has been reported that the probability (odds ratio: OR) of developing IBS 3 months after an episode of infectious diarrhea was 7.58-8.47 times higher than in the control population, but at 24 to 36 months the OR had descended to 3.85-4.05. 10, 66 Regarding the causal agent of PI-IBS, the studies on incidence and prevalence generally refer to clinical presentations of IBS after bacterial infections or the cause is not specified. The most frequently identified bacteria have been E. coli, Campylobacter, Shigella, and Salmonella. 10, 67, 68, 77, 80 E. coli was the cause in the majority of the patients presenting with PI-IBS after an episode of traveler's diarrhea acquired in Mexico. 80 In a group of patients in Houston (Texas) 16.1% of the patients with PI-IBS had previously travelled abroad, whereas only 7.5% of the patients with non PI-IBS had done so. 69 A study conducted on children reported PI-IBS in 10.5% after Campylobacter infection, compared with IBS in 2.5% of the children that were not exposed. 71 On the other hand, bacterial gastroenteritis due to Campylobacter is followed by IBS more frequently than by infectious diseases that do not affect the digestive tract, such as infectious mononucleosis, for example. 81 With respect to gastroenteritis of viral etiology, Norovirus has been described as causing PI-IBS; the results of the 2 published studies on this 75, 85 coincide, reporting that 21.5 and 23.6% of the patients had PI-IBS, whereas only 1.5 and 4.4% of the controls had IBS. In relation to the role of intestinal parasites, the results are less conclusive. A Central American study found no differences in IBS prevalence according to the Rome II criteria in individuals with a history of parasitosis vs subjects with no such history (16.6% vs 15.4%). 73 On the other hand, after a giardiasis outbreak that infected a large number of Norwegians, the prevalence of IBS according to the Rome III criteria was noticeably higher than in the control population (46 vs 14%). 74 Likewise, in an outbreak of Trichinella britovi in Turkey that resulted in 72 cases of infection, 10 developed IBS (13.9%). 83 In reference to the risk factors for developing PI-IBS, the female sex, the severity of gastroenteritis, and the presence of anxiety and depression have been described. 10 Villani et al. analyzed the subjects that developed PI-IBS 2 to 3 years after the Walkerton epidemic, and found that genetic variations associated with the expression of the Tolllike receptor (TLR)-9 related to innate immunity, interleukin (IL)-6 associated with immune activation, and cadherin-1 (CDH1) involved in tight epithelial junctions, were independent risk factors for PI-IBS. 76 The above allows us to conclude that the incidence and prevalence of PI-IBS are variable and even though the bacterial etiology has been studied the most, it appears that viruses such as the Norovirus and parasites such as Giardia may also be related to PI-IBS. In addition, risk factors such as the female sex, severity of gastroenteritis, and previous anxiety and depression, as well as genetic factors associated with immunity, have been determined.
4. Low-grade intestinal inflammation related to post-infectious and non-post-infectious irritable bowel syndrome • There is evidence that suggests the presence of low-grade intestinal inflammation in a subgroup of IBS patients, which involves an increase in intraepithelial T lymphocytes (IEL), mast cells and enterochromaffin cells (level 3 a evidence, grade B recommendation). • The increase in IEL and mast cells appears to be more commonly observed in patients with IBS-D, compared with IBS-C and IBS-M; however, whether there are differences between PI-IBS and non PI-IBS cannot be concluded (level 3 a-b evidence, grade B recommendation). • There is insufficient evidence to determine whether there are differences in the enterochromaffin cells between PI-IBS and non PI-IBS (level 5 evidence, grade D recommendation).
A total of 29 articles were identified; 2 were systematic reviews 89, 90 and the rest were original ones.
91---117
Twenty-seven studies were identified in the initial search 90---115,117 and 2 89, 116 were later selected from other sources. All the studies were conducted on adult population, with the exception of one on pediatric population. Twenty-four studies analyzed the presence of chronic inflammatory cells (T lymphocytes, mast cells, and enterochromaffin cells) in the mucosa of the colon and rectum in IBS patients and controls 89 ,91,94---104,107---108,110---118 (Table 5) .
For several years there have been reports on the increase in the number of enterochromaffin cells in rectal biopsies of PI-IBS patients.
99---100, 106 Spiller et al. reported an up to 5 times higher increase in the number of enterochromaffin cells positive for synaptophysin in patients with C. jejuni infection. 95 A gradual decrease in the number of enterochromaffin cells was observed in these patients in biopsies taken 6 and 12 weeks after infection; however, one year after the acute infection in the subgroup of patients that remained symptomatic, that is, those with PI-IBS, the number of enterochromaffin cells remained elevated, in a range similar to that observed 2 weeks after the C. jejuni infection. The higher number of enterochromaffin cells may have pathophysiologic importance because these cells are the main source of serotonin (5-HT) storage in the organism and there is evidence of an increase in 5-HT release in IBS patients.
119---120 The prokinetic and secretory effect of 5-HT may be related to the diarrhea or liquid stools that accompany IBS-D. A recent systematic review 89 concluded that despite the fact that some researchers have observed an increase in the number of enterochromaffin cells and in the production of serotonin in the mucosa of the colon and rectum in IBS patients, compared with healthy controls, many others have not confirmed such findings. The results show that these changes are not consistent.
In addition, some studies have demonstrated a rise in the number of IEL in both IBS-D and PI-IBS, mainly after acute gastroenteritis due to C. jejuni or Shigella. 95, 111, 117 Nevertheless, it is not completely known if there is also an increase in T lymphocytes in non PI-IBS. In fact, only 7 studies compare PI-IBS and non PI-IBS with respect to the inflammatory changes encountered through histology.
92,94,99---100,108,110---111
Dunlop et al. found a higher number of enterochromaffin cells and IEL in PI-IBS than in non PI-IBS and the controls in 2 studies, and therefore suggest that they could be markers for PI-IBS.
99---100 Likewise, Lee et al. observed a greater number of enterochromaffin cells, IEL, and mast cells in rectal biopsies in PI-IBS patients, compared with non PI-IBS patients and healthy controls. 108 An increase in the number of mast cells in non PI-IBS was observed only in those patients with IBS-D, not in patients with IBS-C or IBS-M. The rise in the number of mast cells had been previously described by Weston et al. in biopsies of the terminal ileum in patients with IBS, compared with the control group, but no differentiation was made between PI-IBS and non PI-IBS. 93 Other researchers later confirmed the increase in the number of these cells in IBS, 96, 98, 101, 106 mainly in the IBS-D subgroup, in the patients with PI-IBS, as well as in those with non PI-IBS. Furthermore, the mast cells 95---96,98,101,106 appear to be near the sensory neurons, and there is a positive correlation with the severity and frequency of pain and/or abdominal discomfort when they are in closer proximity. LPL CD8 ascending colon, IBS: 16.9 ± 5.9 vs UC in remission: 20.4 ± 5.1 vs active UC: 16.4 ± 6.9 vs controls: 10.6 ± 4.4 (IBS, UC remission vs controls, p = 0.01; active vs controls, p = 0.05); no differences in the sigmoid or CD4 in the ascending or sigmoid; PI-IBS vs non PI-IBS was not analyzed 3b The studies are organized from higher to lower level of evidence and then in the progressive order of the year of publication. In regard to the Systematic Reviews, the country corresponds to that of the authors that conducted the study. In the diagnostic criteria/study groups and n columns the corresponding subgroup of those with IBS is in parentheses. C: constipation; CD: celiac disease; D: diarrhea; ECC: enterochromaffin cells; FD: functional dyspepsia; GE: gastroenteritis; HPF: high power field; IEL: intraepithelial lymphocytes; IBD: inflammatory bowel disease; IBS: irritable bowel syndrome; LE: level of evidence; LPL: lamina propria lymphocytes; NCCP: noncardiac chest pain; Non PI: non-post-infectious; N: number; PI: post-infectious; RCT: randomized controlled trial; UC: ulcerative colitis.
In contrast, Braak et al. reported a decrease in the IEL, macrophage, and mast cell count in the colonic mucosa in 66 patients with IBS, compared with 20 healthy controls. 115 In that study, the difference between PI-IBS and non PI-IBS was not specifically analyzed, but rather the patients with acute and gradual IBS onset were compared, and a lower number of macrophages was observed in those with gradual IBS onset. 115 It is likely that the sudden onset group corresponds to PI-IBS, but we cannot conclude that. Previously, another study by the same group in Holland not only found a lower number of mast cells in biopsies of the rectum and descending colon in IBS, but also reduced tryptase release, compared with the controls. 91 Finally, Chang et al. found no differences in the number of immune cells in the colonic mucosa between patients with non PI-IBS and the controls. 116 The above suggests that there is an increase in IEL, mast cells, and enterochromaffin cells in the intestinal mucosa in a group of patients with IBS that appears to be more frequent in those with IBS-D. However, it cannot be determined whether this low-grade inflammation is characteristic of PI-IBS or non PI-IBS. Eight articles related to bowel function 22---23,35,60,94,121---123 were identified in the initial search and 3 additional articles 104,124---125 were identified from other sources ( Table 6 ). The evidence suggests that the changes in the microbiota of the patients with IBS have an influence on visceral sensitivity and gastrointestinal motility, especially at the antroduodenal and colorectal level. 22---23,35,60,94,121---126 Regarding the sensory distubances, the studies have shown that some patients with IBS and dysbiosis (PI-IBS and IBS with SIBO) develop rectal hypersensitivity, one of the most characteristic pathophysiologic findings in IBS. 94 Various studies have also described that patients with PI-IBS have faster colonic transit time. For example, Gwee et al. demonstrated that subjects with a history of gastroenteritis and IBS had faster colonic transit than a control group of healthy subjects (median colonic transit time of 34.4 vs 55.2 min, p = 0.01). 94 In contrast, Yu et al. found that the orocecal transit time correlated with the IBS subtype. 35 Thus, orocecal transit is longer in patients with IBS-C than in those with IBS-D (p = 0.0023).
Moreover, in patients with IBS and evidence of SIBO alterations in the number and frequency of phase III activities of the migrating motor complex (MMC) have been described. 22---23,121 For example, in a group of patients with IBS according to the Rome I criteria and SIBO based on a positive LBT, Pimentel et al. demonstrated that the number of events of phase III of the MMC was lower in patients with IBS and SIBO than in the healthy controls (0.7 vs 2.2, p < 0.001); the same was true for the phase III duration (305 vs 428 s, p < 0.001). 121 Numerous studies have suggested that patients with IBS have qualitative changes in the colonic flora. For example, there are descriptions of patients that can develop a proliferation of bacterial species that produce more gas, specifically methane. The presence of methanogenic flora in patients with IBS has been associated with a slower colonic transit time, rectal hyposensitivity, and altered intestinal motility. 122---125 In a recent analysis of the microbiota in patients with IBS through the technique of pyrosequencing, Jeffery et al. demonstrated that 17 taxas are associated with a slow colonic transit time (including those of the following phylotypes: Euryarchaeota, those of the class: Methanobacteria, and those of the families: Methanobacteriaceae and Desulfohalobiaceae). 60 Likewise, the presence of Proteobacteria is described as being associated with an increase in the pain threshold during rectal distension, evaluated using a barostat. In addition, the first evidence in IBS of the detection of different levels of acetic acid, propionic acid, and total fatty acids has been reported. The highest levels are associated with poor outcome IBS.
In summary, the evidence suggests that changes in the composition of the microbiota or its instability (dysbiosis) have an influence on the gastrointestinal physiology, producing abnormalities in visceral sensitivity and gastrointestinal motility. However, further studies are required in order to determine the effect of the microbiota on those sensory and motor alterations. On the other hand, it is not known whether these disturbances contribute to symptom generation or whether they are the consequence of primary motility disorders. Finally, it should be stressed that there are other factors that have an influence on the microbiota of patients with IBS, such as the type of diet (i.e. FODMAPs: fermentable oligosaccharides, disaccharides, monosaccharides and polyols) and the use of antibiotics. 18,33,131---143 all studies on adults, except one conducted on the pediatric population. 135 An additional original article that had been published in December 2013 was added 37 (Table 7) .
6. Antimicrobials in the treatment
Basically 2 antibiotics have been studied in IBS: rifaximin and neomycin. Rifaximin is a semi-synthetic antibiotic, an analog of rifamycin, designed to have little gastrointestinal absorption. It inhibits the bacterial synthesis of RNA by binding to the RNA polymerase ␤ subunit that is dependent on bacterial DNA. 144 Its absorption is less than 0.4%, making it an almost completely luminal-acting antibiotic, and most of it is excreted in the fecal matter, unchanged. It has a broad spectrum of activity against Gram-positive, Gram-negative, aerobic, and anaerobic enteropathogens 145---146 with a low probability of bacterial resistance. 147---148 In vitro it induces CYP3A4, but its interaction with other medications is almost null. 129 In the selected reviews, 15,127---131 a short cycle of non-absorbable antibiotics, like rifaximin, has been recommended for improving global IBS symptoms. 131 The authors of a systematic review with only 3 original articles on rifaximin treatment of IBS with or without SIBO concluded that rifaximin at a dose of 400 mg BID for 7 to 10 days, improves IBS symptoms, regardless of whether SIBO is present or not. 129 In 2 later systematic reviews with meta-analyses published 2 years apart, the second one with 10 times more patients treated with rifaximin vs placebo, it was concluded, and with a good level of evidence, that the antibiotic at doses of 400 to 550 mg, 2 to 3 times/day, was twice as effective as the placebo at improving IBS symptoms. 15, 127 Additionally, rifaximin showed a therapeutic gain of 9.8 over the placebo and a number needed to treat (NNT) of 10.2 for global IBS improvement and very similar values for abdominal bloating improvement. 15, 127 In another systematic review on the treatment of abdominal bloating, it was concluded that rifaximin was superior to placebo in the proportion of patients with IBS-Non C that reported subjective improvement in abdominal bloating. 129 The original articles analyzed rifaximin and neomycin, as well as a few other antibiotics. However, the studies have different designs and include retrospective studies, case series, and randomized controlled trials with placebo or other antibiotics and different doses. For example, rifaximin has been studied from doses of 200 mg QID, 137 400 mg BID or TID for 7 to 14 days, to 550 mg TID for 14 days. 15 Likewise, the outcome variables analyzed were very different in each of the studies, from global IBS improvement to improvement of secondary symptoms such as pain and/or abdominal bloating, to the frequency and consistency of bowel movements. 131, 132, 134 The effect of rifaximin on GBT 136, 137 or LBT 33 has been evaluated as well. These differences in the studies make it difficult to arrive at a conclusion. Nevertheless, the best evidence comes from the recent Target 1 and Target 2 studies by Pimentel et al., with more than 1,200 patients between the 2 investigations. 134 They show that rifaximin at a dose of 550 mg TID for 14 days in patients with IBS-Non C by Rome II criteria resulted in a greater proportion of patients with adequate relief from IBS symptoms, abdominal bloating, daily symptom intensity, abdominal pain, and stool consistency. 134 In the follow-up at 10 weeks post-treatment, adequate relief defined as the subjective report of symptom improvement in at least one of every 2 weeks, rifaximin remained significantly superior to placebo. It is worth noting that it had previously been reported that at lower doses, such as 400 mg BID or TID for 10 days, rifaximin was also superior to placebo in the percentage of patients that reported overall improvement of IBS. 131---132 Regarding secondary effects, in the Target 1 and 2 studies, which are the largest, frequency was similar to the placebo (1.6% with rifaximin and 2.4% with placebo) and the main effects in order of frequency were headache, followed by respiratory tract infections, abdominal pain, nausea, and diarrhea. 134 Furthermore, rifaximin can neutralize LBT in 52% of the patients with Rome II-IBS and in this subgroup symptom severity improved, but the corresponding study was not controlled, 33 and neither were those that evaluated the effect on GBT. 136, 137 Regarding the effect on children, a dose of 550 mg TID for 10 days showed no differences from the placebo or in LBT normalization, which was achieved in only 20%. 135 This suggests that children most likely require higher doses or a different type of antibiotic, probably due to a more resistant microbiota. In reference to rifaximin retreatment, only one retrospective study analyzed this modality; patients treated up to 5 times had a mean interval of symptom recurrence of 4 months. 143 Effectiveness was 75%, similar to that of the first treatment. However, welldesigned studies are required in order to determine how often rifaximin can be repeated. 143 Finally, no studies have evaluated the long-term effects of rifaximin in IBS.
Regarding neomycin, it is a systemic aminoglycoside that has been evaluated in 2 original studies on IBS, 18,138 both of which are randomized and controlled with placebo. At a dose of 500 mg BID for 7 to 10 days in patients with IBS in general in one study, and IBS-C by Rome I criteria in the other, neomycin was superior to the placebo in the percentage of patients, mainly those with a positive LBT, that reported improvement in a composite score of symptoms including abdominal pain, diarrhea, bloating, and bowel habit. 18 Neomycin normalized LBT in only 20% of the patients, but in the methane-positive patients, the percentage that reported improvement in regard to constipation was 9 times higher with neomycin than with placebo. 138 Despite this, neomycin is not an ideal drug for IBS because of its characteristics in relation to systemic absorption and its safety spectrum.
With regard to other antibiotics, a retrospective study was conducted that compared rifaximin with neomycin, doxycycline, and amoxicillin-clavulanic acid that were used in the management of the treatment and retreatment of SIBO in patients with IBS; 141 however, these agents were not as effective as rifaximin. Erythromycin has also been studied, evaluating the number of days until IBS symptom recurrence after LBT neutralization, but it was much less effective than tegaserod. 142 And finally, rifaximin together with metronidazole has been evaluated in post-giardiasis-IBS, but no conclusion can be reached in relation to this study. 139 
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